Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02164006
Title Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications

Hodgkin's lymphoma

Therapies

Umbralisib

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
TG Therapeutics Investigational Trial Site Duarte California 91010 United States Details
TG Therapeutics Investigational Trial Site San Diego California 92093 United States Details
TG Therapeutics Investigational Trial Site Sarasota Florida 34232 United States Details
TG Therapeutics Investigational Trial Site Detroit Michigan 48201 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field